
|Articles|March 1, 2003
So Far, So Good
Paris - Citing ease of application and time savings as the key advantages, Jean-Marie Lachapelle, M.D., characterized Allerderm's T.R.U.E. Test as "a step forward in the technology of patch testing that ensures an optimal penetration and delivery of allergens through the skin."
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














